Carolyn Ng, Ph.D.

TPG Life Sciences Innovations, Business Unit Partner

cng@tpg.com

Carolyn Ng, Ph.D. is a Business Unit Partner at TPG Life Sciences Innovations, where she leads investments in transformative early- to mid-stage companies across a range of therapeutic areas. Dr. Ng currently serves on the boards of directors for Bicara Therapeutics (NASDAQ: BCAX), Mbrace Therapeutics, and Adcendo. Before joining TPG in 2021, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she co-led the investment team. During her tenure, she held board positions with several high-impact public and private life sciences companies, including Bicycle Therapeutics PLC (NASDAQ: BCYC), Boundless Bio, Obsidian Therapeutics, 28-7 Therapeutics, Epirium Bio, Nuvaira, and served as a board observer for Visterra (acquired by Otsuka Pharmaceutical). Dr. Ng is a passionate advocate for advancing the life sciences industry. She currently serves on the board of Biocom California and mentors emerging leaders as part of the Women in Bio Boardroom Ready Program. Additionally, she is a member of Singapore’s Therapeutics Development Review Panel, which identifies and funds high- potential drug discovery and development initiatives from public research teams in Singapore. She earned her Ph.D. in Cancer Molecular Biology from the National University of Singapore, where she was awarded the prestigious NGS Integrative Sciences and Technology Ph.D. Scholarship.